首页 > 技术支持 > 文献速递

Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade

Cell

Immune checkpoint blockade has transformed cancer therapy, but immune-related adverse events (irAEs) remain a major, sometimes fatal, limitation, and the lack of robust preclinical models has hindered mechanistic insight. We present the lifestyle-induced susceptibility to irAEs (LISA) model, in which diet-driven metabolic and microbial alterations recreate human-like susceptibility to anti-PD-1 toxicity. LISA recapitulates multi-organ irAEs with immune infiltration and cytokine production, severity depending on sex, age, treatment modality, and immunotherapy response. Mechanistically, dysbiosis marked by Akkermansia muciniphila enrichment accompanies aberrant immune activation, driving regulatory T cell (Treg) fragility and CD8+ cytotoxic effector populations, both observed in patients with irColitis. Dietary reversal, metabolite supplementation, and blocking interferon (IFN)-γ production or signaling in Tregs restored Treg stability and resolved inflammation.

Related products

Catalog No. Product Name Description Target
MS870209 InVivo Plus Anti-Mouse PD-1 Antibody (29F.1A12) InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (29F.1A12) [29F.1A12] (MS870209) is a rat monoclonal antibody detecting Programmed cell death protein 1 in FCM, IF, IHC, Neutralization, WB. Suitable for Mouse. Highlights ●Multi-Application — Validated across multiple applications. ●Flow Cytometry — Validated for flow cytometry applications. CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, PD-1